VBX-1000
Phase 2- Indications
- Periodontal disease
Company intelligence / Profile preview
Vetbiolix
Loos, Nord, Francevetbiolix.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Positive results reported from Proof of Concept study with VBX-1000 (previously MIV-701) and from Osteoarthritis Clinical Study in Dogs. Currently running two open-label, multicenter Proof-of-Concept clinical studies for VBX-3000 in dogs and cats with gut motility disorders, with final results expected by Q2-2025[5].
- Therapeutic areas
- GastroenterologyRheumatologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Veterinary
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
MedivirCan-Fite BioPharmaRaQualia Pharma
Beyond the preview
Go deeper on Vetbiolix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vetbiolix.